Barriers to Prescribing Targeted Therapies for Patients With NSCLC With Highly Actionable Gene Variants in the Veterans Affairs National Precision Oncology Program.
Vishal VashisthaJenna ArmstrongDavid WinskiPradeep J PoonnenBradley J HintzeMeghan PriceJane L SnowdonDilhan WeeraratneDavid BrotmanGretchen P JacksonMichael J KelleyPublished in: JCO oncology practice (2021)
A substantial minority of patients with NSCLC bearing highly actionable gene variants are not prescribed targeted agents. Further provider- and pathologist-directed educational efforts and implementation of health informatics systems to provide real-time decision support for test ordering and interpretation are needed.
Keyphrases
- copy number
- quality improvement
- primary care
- small cell lung cancer
- healthcare
- genome wide
- advanced non small cell lung cancer
- public health
- mental health
- genome wide identification
- palliative care
- brain metastases
- transcription factor
- machine learning
- emergency department
- gene expression
- risk assessment
- adverse drug
- electronic health record
- climate change
- tyrosine kinase